Home » Research » SARC ACTIVE Clinical Trials
Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world.
Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
TYPE OF SARCOMA: Advanced Dedifferentiated LiposarcomaDRUG: Abemaciclib
ACCRUAL STATUS: Now recruiting for patients
Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
TYPE OF SARCOMA: OsteosarcomaDRUG: Regorafenib, Nivolumab
ACCRUAL STATUS: Not recruiting
A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging
TYPE OF SARCOMA: Ewing SarcomaDRUG: Trabectedin and Irinotecan
ACCRUAL STATUS: Not Recruiting
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
TYPE OF SARCOMA: Epithelioid HemangioendotheliomaDRUG: Trametinib
A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
TYPE OF SARCOMA: Soft Tissue Sarcoma of the ExtremityDRUG: Pembrolizumab
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)DRUG: Selumetinib in Combination with Sirolimus